Table 1.
Distribution of Proteins in Plasma From Patients With Glioma WHO Grade II–IV
| Protein | Dir | Astrocytoma WHO Grade II–III vs GBM | Dir | Astrocytoma WHO Grade II–III vs Oligodendroglioma WHO Grade II–III |
|---|---|---|---|---|
| P a | P a | |||
| Caspase-8 (CASP-8) | — | .14 | U | .0049 |
| C-C motif chemokine 4 (CCL4) | U | .025 | — | .19 |
| C-C motif chemokine 19 (CCL19) | U | .0051 | — | .80 |
| T-cell surface glycoprotein CD5 (CD5) | U | .0010 | — | .76 |
| CD70 antigen (CD70) | U | .0050 | — | .76 |
| CD83 antigen (CD83) | U | .0048 | — | .60 |
| Natural killer receptor 2B4 (CD244) | U | .026 | — | .053 |
| CD 40 ligand (CD40-L) | — | .10 | U | .029 |
| C-X-C motif chemokine 13 (CXCL13) | D | .023 | — | .68 |
| Pro-epidermal growth factor (EGF) | — | .24 | U | .022 |
| Tumor necrosis factor ligand superfamily member 6 (FASLG) | U | .041 | — | .24 |
| Granzyme A (GZMA) | U | .025 | — | .97 |
| Granzyme B (GZMB) | U | .0043 | — | .13 |
| Galectin-1 (Gal-1) | U | .036 | — | .26 |
| Interleukin-12 (IL-12) | U | .0005 | — | .91 |
| Interleukin-1 alpha (IL-1α) | — | .92 | D | .0025 |
| C-C motif chemokine 8 (MCP-2) | U | .014 | — | .18 |
| Matrix metalloproteinase-12 (MMP-12) | U | .0026 | — | .97 |
| Programmed cell death protein 1 (PDCD1) | U | .0040 | — | .65 |
| Programmed cell death 1 ligand 2 (PD-L2) | U | .042 | — | .78 |
| Pleiotrophin (PTN) | U | .0014 | — | .29 |
| Tumor necrosis factor receptor superfamily member 9 (TNFRSF9) | U | .032 | — | .87 |
| Tumor necrosis factor receptor superfamily member 21 (TNFRSF21) | U | .015 | — | .56 |
| Tumor necrosis factor ligand superfamily member 12 (TWEAK) | U | .0002 | — | .097 |
Age and sex are included in the analysis. Bold values represent P < .05. D, downregulated; Dir, direction; U, upregulated.
aGeneral linear model.